The construction of Mindray Wuhan Center, with a total investment of RMB 4.5 billion, was officially launched in
Wuhan East Lake High-tech Development Zone (also known as Optics Valley) on June 20, 2020.
The project includes two major subprojects of Wuhan Research Institute and Manufacturing Center. The total net
area is about 271 mu（18 hectacres）and the total construction area is about 620,000 square meters. Wuhan Research
Institute and Wuhan Manufacturing Center will become Mindray’s second largest R&D center upon completion.
Message from Cheng Minghe, President of Mindray
Li Xiting, Chairman of Mindray, Cheng Minghe, President of Mindray and Li Zaiwen, Senior Vice President of
Mindray, together with Vice President and General Manager of Wuhan Research Institute Huang Haitao, and
Executive Vice President Liu Laiping attended the groundbreaking ceremony. Wang Zhonglin, party chief of Wuhan
and the city’s mayor Zhou Xianwang were also present.
Construction is now underway
“The implementation of Mindray Wuhan Center is gathering the upstream and downstream industrial chains, helping
Wuhan build a biomedical and medical device industry cluster, and accelerating the promotion of 'Big Health
industry' development", said Mr. Zhou, the city's mayor.
Mindray Wuhan Research Institute is located in the High-tech Medical Devices Zone, Optics Valley Biolake. The
institute comprises of five sections, biomaterial R&D center, surgical equipment R&D center, “Big Health”
technology R&D center, global service support center and engineering technology transformation center. The new
global R&D center of Mindray is expected to establish a 2,000 member’s staff in five years, including 1,200
high-end R&D personnel, to embark on a new journey with scientific exploration of Mindray.
Mindray is committed to putting healthcare within reach
Settled down in the Jiulong Industrial Base of Optics Valley Biolake, Mindray Wuhan Manufacturing Center is
designed to become equipment manufacturing centers and engineering centers for orthopedic surgery (surgical
robots), minimally invasive surgery and “Big Health”, reagent manufacturing center, biological raw material
preparation center and supporting facilities. The industrial output value is expected to be no less than RMB 3
billion when the base is in full operation.
Upon completion, Mindray Wuhan Center will become a distinctive R&D, manufacturing and operation center of
medical equipment system, biological raw materials, core components etc., in China. Taking independent
innovation as the key driving force, Mindray will build a medical innovation highland to support the development
of medical innovation technology.